P.39 Docetaxel plus epirubicin (DE) vs docetaxel plus capecitabine (DC) as 1st line treatment in patients with locally advanced and metastatic breast cancer: a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)
In: Critical Reviews in Oncology/Hematology, Jg. 64 (2007-11-01), S. S49
Online
unknown
Zugriff:
Titel: |
P.39 Docetaxel plus epirubicin (DE) vs docetaxel plus capecitabine (DC) as 1st line treatment in patients with locally advanced and metastatic breast cancer: a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)
|
---|---|
Autor/in / Beteiligte Person: | Vardakis, N. ; Mavroudis, D. ; Varthalitis, Ioannis ; Kouroussis, Ch. ; Kalbakis, Kostas ; Karampeazis, A. ; Vamvakas, L. ; Souglakos, I. ; Ardavanis, Alexandros ; Malamos, N. |
Link: | |
Zeitschrift: | Critical Reviews in Oncology/Hematology, Jg. 64 (2007-11-01), S. S49 |
Veröffentlichung: | Elsevier BV, 2007 |
Medientyp: | unknown |
ISSN: | 1040-8428 (print) |
DOI: | 10.1016/s1040-8428(13)70212-9 |
Schlagwort: |
|
Sonstiges: |
|